BOLT Stock Forecast 2025-2026
Distance to BOLT Price Targets
BOLT Price Momentum
🤔 Considering Bolt Biotherapeutics (BOLT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest BOLT Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, BOLT has a neutral consensus with a median price target of $1.75 (ranging from $1.50 to $2.00). The overall analyst rating is Buy (6.0/10). Currently trading at $0.41, the median forecast implies a 322.7% upside. This outlook is supported by 0 Buy, 3 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Stephen Willey at Stifel, suggesting a 262.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BOLT Analyst Ratings
BOLT Price Target Range
Latest BOLT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BOLT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| May 15, 2024 | Jones Trading | Soumit Roy | Hold | Downgrade | $0.00 |
| May 15, 2024 | Guggenheim | Michael Schmidt | Neutral | Downgrade | $0.00 |
| May 15, 2024 | Stifel | Stephen Willey | Hold | Downgrade | $1.50 |
| May 15, 2024 | Leerink Partners | Daina Graybosch | Market Perform | Downgrade | $1.00 |
| May 15, 2024 | HC Wainwright & Co. | Edward White | Neutral | Downgrade | $0.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $8.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Aug 3, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Jun 5, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| May 26, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| May 12, 2023 | SVB Leerink | Daina Graybosch | Outperform | Upgrade | $4.00 |
| May 12, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Mar 30, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Jan 24, 2023 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $3.00 |
| Oct 4, 2022 | HC Wainwright & Co. | Edward White | Buy | Initiates | $8.00 |
| Aug 11, 2022 | SVB Leerink | Daina Graybosch | Market Perform | Downgrade | $4.00 |
| May 17, 2022 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $5.00 |
| Jan 6, 2022 | Morgan Stanley | Matthew Harrison | Equal-Weight | Downgrade | $11.00 |
Bolt Biotherapeutics Inc. (BOLT) Competitors
The following stocks are similar to Bolt Biotherapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bolt Biotherapeutics Inc. (BOLT) Financial Data
Bolt Biotherapeutics Inc. has a market capitalization of $15.85M with a P/E ratio of -0.2x. The company generates $9.78M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -54.9% quarter-over-quarter, while maintaining an operating margin of -1,441.1% and return on equity of -65.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Bolt Biotherapeutics Inc. (BOLT) Business Model
About Bolt Biotherapeutics Inc.
Develops immunotherapies for cancer treatment.
Bolt Biotherapeutics operates as a clinical-stage biotechnology company, focusing on the development of immunotherapies that utilize its proprietary Boltbody™ ISAC platform. By targeting and activating the body's immune system to destroy tumor cells, the company seeks to create innovative treatment options, likely generating revenue through partnerships, licensing agreements, and eventual product sales.
Founded in 2015 and based in Redwood City, California, Bolt Biotherapeutics is positioned within the health sciences and pharmaceutical sectors, contributing to the advancement of targeted cancer therapies. The company's work is part of the expanding field of immuno-oncology, which is crucial for developing long-lasting cancer treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Mr. William P. Quinn
Country
United States
IPO Year
2021
Website
www.boltbio.comBolt Biotherapeutics Inc. (BOLT) Latest News & Analysis
Bolt Biotherapeutics (Nasdaq: BOLT) will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 p.m. as part of its ongoing development of cancer immunotherapies.
Bolt Biotherapeutics' conference participation signals potential insights into its pipeline and strategy, influencing market perception and stock performance in the competitive biopharmaceutical sector.
Bolt Biotherapeutics and Toray Industries are collaborating to develop an immune-stimulating antibody conjugate targeting Caprin-1 for treating solid tumors, leveraging proprietary technologies from both companies.
Bolt Biotherapeutics' collaboration with Toray on a novel cancer treatment targeting Caprin-1 could advance cancer therapies, potentially increasing market value and attracting investor interest in biotech innovation.
Bolt Biotherapeutics, Inc. reported a quarterly loss of $0.40 per share, exceeding the Zacks Consensus Estimate of a $0.36 loss, but an improvement from a $0.43 loss per share a year prior.
BOLT's quarterly loss exceeded expectations, indicating potential operational challenges. A smaller year-over-year loss may signal improvement, but missed estimates could raise concerns about future profitability.
Bolt Biotherapeutics (Nasdaq: BOLT) reported positive preclinical results for BDC-4182, showing strong anti-tumor activity and safety. Findings from BDC-1001 suggest improved efficacy for future trials.
BDC-4182's promising preclinical results and enhanced efficacy potential could drive investor interest in Bolt Biotherapeutics, impacting stock performance and market confidence in its immunotherapy portfolio.
The Schall Law Firm is reminding investors of a class action lawsuit against Bolt Biotherapeutics (NASDAQ:BOLT) for securities violations during the period of February 5, 2021 to May 14, 2024.
A class action lawsuit against Bolt Biotherapeutics for securities violations could impact stock value and investor sentiment, signaling potential legal and financial risks.
A class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) and some of its officers, as announced by Pomerantz LLP on September 3, 2024.
A class action lawsuit against Bolt Biotherapeutics could lead to financial penalties, reputational damage, and affect stock performance, impacting shareholder value and investment decisions.
Frequently Asked Questions About BOLT Stock
What is Bolt Biotherapeutics Inc.'s (BOLT) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Bolt Biotherapeutics Inc. (BOLT) has a median price target of $1.75. The highest price target is $2.00 and the lowest is $1.50.
Is BOLT stock a good investment in 2025?
According to current analyst ratings, BOLT has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BOLT stock?
Wall Street analysts predict BOLT stock could reach $1.75 in the next 12 months. This represents a 322.7% increase from the current price of $0.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bolt Biotherapeutics Inc.'s business model?
Bolt Biotherapeutics operates as a clinical-stage biotechnology company, focusing on the development of immunotherapies that utilize its proprietary Boltbody™ ISAC platform. By targeting and activating the body's immune system to destroy tumor cells, the company seeks to create innovative treatment options, likely generating revenue through partnerships, licensing agreements, and eventual product sales.
What is the highest forecasted price for BOLT Bolt Biotherapeutics Inc.?
The highest price target for BOLT is $2.00 from at , which represents a 383.1% increase from the current price of $0.41.
What is the lowest forecasted price for BOLT Bolt Biotherapeutics Inc.?
The lowest price target for BOLT is $1.50 from Stephen Willey at Stifel, which represents a 262.3% increase from the current price of $0.41.
What is the overall BOLT consensus from analysts for Bolt Biotherapeutics Inc.?
The overall analyst consensus for BOLT is neutral. Out of 7 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $1.75.
How accurate are BOLT stock price projections?
Stock price projections, including those for Bolt Biotherapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
